Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

Mark Bustoros^{1

2}, Efstathios Kastritis³, Romanos Sklavenitis-Pistofidis^{1

2}, Chia-Jen Liu^{1

2}, Kalvis Hornburg^{1

2}, Nikolaos Kanellias³, Geon Kim², David Liu², Maria Gavriatopoulou³, Catherine R Marinac^{1

4}, Maria Roussou³, Magdalini Migkou³, Kimberly Noonan^{1

2}, Kaitlen Reyes^{1

2}, Bradley Rivotto^{1

2}, Carl Jannes Neuse^{1

2}, Dimitrios C Ziogas³, Jacob Laubach^{1

2}, Evangelos Terpos³, Kenneth C Anderson², Paul G Richardson^{1

2}, Irene M Ghobrial^{1

2}, Meletios A Dimopoulos³

Affiliations

¹ Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
³ Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
⁴ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

PMID: 30773670
DOI: 10.1002/ajh.25441

Free article

Clinical Trial

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

Mark Bustoros et al. Am J Hematol. 2019 May.

Free article

. 2019 May;94(5):E146-E149.

doi: 10.1002/ajh.25441. Epub 2019 Mar 6.

Authors

Affiliations

¹ Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
³ Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
⁴ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

PMID: 30773670
DOI: 10.1002/ajh.25441

No abstract available

PubMed Disclaimer

Cited by

Progress in the Management of Smoldering Multiple Myeloma.
Schmidt TM, Callander NS. Schmidt TM, et al. Curr Hematol Malig Rep. 2021 Apr;16(2):172-182. doi: 10.1007/s11899-021-00623-7. Epub 2021 May 13. Curr Hematol Malig Rep. 2021. PMID: 33983517 Review.
How we manage smoldering multiple myeloma.
Romano A, Cerchione C, Conticello C, Martinelli G, Di Raimondo F. Romano A, et al. Hematol Rep. 2020 Sep 21;12(Suppl 1):8951. doi: 10.4081/hr.2020.8951. eCollection 2020 Sep 21. Hematol Rep. 2020. PMID: 33042502 Free PMC article.
What Is New in the Treatment of Smoldering Multiple Myeloma?
Bolli N, Sgherza N, Curci P, Rizzi R, Strafella V, Delia M, Gagliardi VP, Neri A, Baldini L, Albano F, Musto P. Bolli N, et al. J Clin Med. 2021 Jan 22;10(3):421. doi: 10.3390/jcm10030421. J Clin Med. 2021. PMID: 33499196 Free PMC article. Review.
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
Cowan A, Ferrari F, Freeman SS, Redd R, El-Khoury H, Perry J, Patel V, Kaur P, Barr H, Lee DJ, Lightbody E, Downey K, Argyelan D, Theodorakakou F, Fotiou D, Liacos CI, Kanellias N, Chavda SJ, Ainley L, Sandecká V, Pospíšilová L, Minarik J, Jungova A, Radocha J, Spicka I, Nadeem O, Yong K, Hájek R, Kastritis E, Marinac CR, Dimopoulos MA, Get G, Trippa L, Ghobrial IM. Cowan A, et al. Lancet Haematol. 2023 Mar;10(3):e203-e212. doi: 10.1016/S2352-3026(22)00386-6. Lancet Haematol. 2023. PMID: 36858677 Free PMC article.
Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges.
Sklavenitis-Pistofidis R, Getz G, Ghobrial I, Papaioannou M. Sklavenitis-Pistofidis R, et al. Front Oncol. 2022 Jul 14;12:961421. doi: 10.3389/fonc.2022.961421. eCollection 2022. Front Oncol. 2022. PMID: 35912171 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

Affiliations

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

Authors

Affiliations

Similar articles

Cited by

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources